3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Glioblastoma
1
Drug-Related Side Effects and Adverse Reactions
1
Depression
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anxiety Disorders
1
All Solid Tumors
1
Interventions
Temozolomide
10
Irinotecan
8
Cyclophosphamide
7
dinutuximab
5
aldesleukin
4
Interleukin-2
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
fludarabine
3
Topotecan
3
Melphalan
3
Isotretinoin
3
Filgrastim
3
gallium Ga 68 dotatate
2
Vincristine
2
TPI-287
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Carboplatin
2
venetoclax
1
trametinib
1
thymoglobulin
1
talazoparib
1
sonidegib
1
silmitasertib
1
plerixafor
1
olaparib
1
naxitamab
1
lutetium Lu 177 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neuroblastoma
×
Pharmaceutical Preparations
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled